All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Hepatocellular carcinoma (HCC), mainly caused by chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, is one of the most commonly diagnosed cancers and the third leading cause of cancer-related death worldwide \[[@pone.0176802.ref001]\]. In 2012, about 782,500 new HCC cases and 745,500 deaths occurred in the world, making the incidence and mortality rates almost equal \[[@pone.0176802.ref002]\]. Although attempts have been made to predict recurrence and prognosis in HCC patients using clinical factors, such as positive portal vein thrombosis, large tumor size, increased serum alpha-fetoprotein (AFP), vascular invasion and advanced tumor node metastasis (TNM) stage, the long-term prognosis remains poor with reported 5-year survival rates ranging from 17% to 53% \[[@pone.0176802.ref003]\]. Therefore it is essential to better understand the mechanism of cancer progression and development in HCC and identify potential biomarkers for prognosis prediction.

Apoptosis is a genetically controlled process of cell suicide, which plays an important role in multicellular organisms \[[@pone.0176802.ref004]\]. As we all know, inappropriate regulation of apoptosis mechanism facilitates the accumulation of somatic mutations and thereby contributes to tumor initiation, progression as well as metastasis \[[@pone.0176802.ref005]--[@pone.0176802.ref006]\]. Caspases (CASPs), members of a conserved family involved in signaling and execution in apoptosis pathways, are cysteine-aspartic acid proteases, which can be broadly divided into initiator (upstream) and effector (downstream) CASPs based on their functions \[[@pone.0176802.ref007]\]. To date, 14 family members have been identified \[[@pone.0176802.ref008]\]. *CASP3*, *CASP6*, and *CASP7* belong to effector CASPs and they execute cell death process; *CASP8*, *CASP9*, and *CASP10* transmit apoptotic signals and they belong to initiator CASPs \[[@pone.0176802.ref009]\]. All known CASPs possess an active-site cysteine and they cleave their substrates after the aspartic acid residue \[[@pone.0176802.ref010]\].

Many studies have shown that genetic polymorphisms in CASP genes are associated with risk of various human cancers, including HCC \[[@pone.0176802.ref009], [@pone.0176802.ref011]--[@pone.0176802.ref015]\]. However, the influence of the CASP genes-related polymorphisms on the prognosis of HCC have not been investigated extensively. Therefore, we selected 7 potentially functional SNPs in *CASP3*, *CASP7*, *CASP8*, *CASP9*, and *CASP10* genes and aimed to determine whether polymorphisms in these genes are associated with prognosis of HCC.

Materials and methods {#sec002}
=====================

Patients {#sec003}
--------

From April 1996 to September 2009, a total of 362 Chinese Han patients with primary HCC newly diagnosed and received surgical resection of HCC tumor were recruited by the Qidong Liver Cancer institute in Qidong, Jiangsu province, China. The clinical outcomes of HCC were recorded until October 2014, with a median follow-up time of 53.0 months, which range from 2 to 110 months. The clinical diagnosis of HCC was based on the National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology and histopathological examination. Patients with secondary liver cancers were excluded from our study. Patients with no other cancers were determined at the initial screening examination and were followed-up every 3months by researchers from the time of enrollment, stopping until death or the last time of follow-up.

There were no restrictions on gender, age and tumor stage for recruitment and 5 ml whole blood was extracted for each subject. Clinical characteristics such as tumor size, differentiation, venous invasion, and son on were collected via medical records with approval of patients. The clinical typing of tumors were determined by the TNM classification system of International Union Against Cancer (edition 6) and the histologic grade of tumor differentiation was assigned by the Edmondson grading system. Overall survival (OS) and disease free survival (DFS) were used as endpoints for the study. OS was calculated from the date of pathologic diagnosis/recruitment to death or the end of available follow-up.

Disease free survival (DFS) was defined as the time from pathologic diagnosis/recruitment to disease recurrence, metastasis, disease specific death or last follow-up.

Written informed consent was obtained from each patient before enrollment, and this study was approved by the Department of Scientific Research of Fudan University as well as the Qidong Liver Cancer Institute.

SNP selection {#sec004}
-------------

To select potentially functional SNPs in *CASP3*, *CASP7*, *CASP8*, *CASP9*, and *CASP10* genes, we utilized the International HapMap Project database (<http://hapmap.ncbi.nlm.nih.gov/>), and the dbSNP database (<https://www.ncbi.nlm.nih.gov/projects/SNP/>). Finally, a total of 7 SNPs were selected for genotyping ([Table 1](#pone.0176802.t001){ref-type="table"}).

10.1371/journal.pone.0176802.t001

###### SNPs selected in CASP genes and their allele frequencies.

![](pone.0176802.t001){#pone.0176802.t001g}

  Gene           Chromosome   Location    Position    SNP          Allele   MAF (CHB)[^a^](#t001fn002){ref-type="table-fn"}   MAF (observed)[^b^](#t001fn003){ref-type="table-fn"}
  -------------- ------------ ----------- ----------- ------------ -------- ------------------------------------------------- ------------------------------------------------------
  ***CASP3***    4q34         5\' flank   185571557   rs12108497   T\>C     0.282                                             0.256
                              5\' flank   185553098   rs2705897    A\>C     0.209                                             0.162
  ***CASP7***    10q25        T244S       115489152   rs2227310    C\>G     0.427                                             0.391
  ***CASP8***    2q33-q34     Intron      202151163   rs3769818    G\>A     0.291                                             0.265
  ***CASP9***    1p36.21      5\' flank   15852034    rs4645978    A\>G     0.379                                             0.368
                              5\' flank   15851483    rs4645981    C\>T     0.214                                             0.136
  ***CASP10***   2q33-q34     L522I       202082459   rs13006529   T\>A     0.185                                             0.184

MAF, minor allele frequency; CHB, Chinese Han in Beijing; SNP, single nucleotide polymorphism.

^a^ MAF in Chinese Han population in Hapmap database.

^b^ MAF in our studied population.

DNA extraction and genotyping {#sec005}
-----------------------------

Genomic DNA was extracted from blood samples using the QIAamp DNA Mini Kit (GIAGEN GmbH, Hilden, Germany). Genotyping was performed with Sequenom MassARRAY iPLEX platform by use of allele-specific MALDI-TOF mass spectrometry assay. Polymerase chain reaction (PCR) and extension primers for these 7 SNPs were designed using the MassARRAY Assay Design 3.0 software (Sequenom). Duplicate test samples and two water samples (PCR negative controls) were included in each 96-well plate. Genotyping quality was examined by a detailed QC procedure consisting of \>95% successful call rate, duplicate calling of genotypes, internal positive control samples.

Statistical analysis {#sec006}
--------------------

The haplotypes were constructed for the genes with at least two SNPs using Bayesian algorithm by PHASE software. Survival curves were estimated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for each analysis by using the Cox proportional hazards regression model. The effects of clinical variables, single SNP and haplotype on OS and DFS were assessed using the Cox proportional hazards regression model and log-rank test. All analyses were performed with SPSS software version 22 (SPSS, Chicago, IL). All tests were two-sided and a *P*\<0.05 was considered statistically significant.

Results {#sec007}
=======

Patient characteristics and clinical predictors {#sec008}
-----------------------------------------------

The clinical pathologic characteristics of the 362 HCC patients and their associations with OS are summarized in [Table 2](#pone.0176802.t002){ref-type="table"}. There were 225 (62.2%) deaths at the time of analysis and the overall median survival time (MST) was 34.0 (95%CI, 27.4--40.6) months. In univariate analysis, tumor size and venous invasion were significantly associated with OS (*P* = 0.028 and 0.029, respectively) and DFS (*P* = 0.042 and 0.026, respectively). However, none of other clinical characteristics was significantly associated with OS or DFS.

10.1371/journal.pone.0176802.t002

###### Clinical characteristics and their prediction of overall survival and disease free survival in HCC patients.
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  **Characteristics**   No of patients   No of events   5-y-survival (%)   MST (95%CI)         Overall survival (OS)   Disease free survival (DFS)                                        
  --------------------- ---------------- -------------- ------------------ ------------------- ----------------------- ----------------------------- ------- ------- -------------------- -------
  **Number**            362              225            30                 34.0 (27.4--40.6)                                                                                              
  **Age (year)**                                                                               0.478                                                         0.410                        
  ≤50                   186              113            30                 35.0 (23.3--46.7)                           1.00                                                               
  \>50                  176              112            29                 33.0 (24.2--41.8)                           1.10 (0.85--1.43)             0.483           1.11 (0.86--1.45)    0.417
  **Sex**                                                                                      0.476                                                         0.665                        
  female                63               41             27                 31.0 (24.2--37.8)                           1.00                                                               
  male                  299              184            30                 37.0 (27.5--46.5)                           0.89 (0.63--1.24)             0.481           0.93 (0.66--1.30)    0.670
  **Smoking**                                                                                  0.265                                                         0.200                        
  never                 224              144            26                 31.0 (23.2--38.8)                           1.000                                                              
  ever                  138              81             37                 39.0 (27.3--50.7)                           0.86 (0.65--1.13)             0.270           0.84 (0.64--1.10)    0.207
  **Drinking**                                                                                 0.615                                                         0.728                        
  never                 142              86             28                 35.0 (19.6--50.4)                           1.00                                                               
  ever                  220              139            31                 33.0 (25.0--41.0)                           1.07 (0.82--1.40)             0.619           1.05 (0.80--1.37)    0.731
  **Family history**                                                                           0.257                                                         0.299                        
  absent                263              158            31                 37.0 (27.3--46.7)                           1.00                                                               
  present               81               55             25                 29.0 (17.4--40.6)                           1.19 (0.88--1.62)             0.262           1.17 (0.86--1.60)    0.306
  unkown                18               18                                                                                                                                               
  **HbsAg**                                                                                    0.599                                                         0.478                        
  negative              59               40             35                 22.0 (6.7--37.3)                            1.00                                                               
  positive              303              185            28                 37.0 (30.2--43.8)                           0.91 (0.65--1.29)             0.603           0.89 (0.63--1.25)    0.484
  **AFP**                                                                                      0.395                                                         0.266                        
  negative              142              95             26                 33.0 (25.7--40.3)                           1.00                                                               
  positive              214              127            32                 35.0 (26.1--43.9)                           0.89 (0.68--1.16)             0.400           0.86 (0.66--1.12)    0.273
  unkown                6                3                                                                                                                                                
  **Tumor size (cm)**                                                                          0.026                                                         0.039                        
  ≤5                    183              107            35                 39.0 (28.1--49.9)                           1.00                                                               
  \>5                   179              118            24                 30.0 (21.0--39.0)                           1.34 (1.03--1.75)             0.028           1.31 (1.01--1.71)    0.042
  **Differentiation**                                                                          0.568                                                         0.390                        
  Ⅰ+Ⅱ                   196              122            28                 37.0 (27.5--46.5)                           1.00                                                               
  Ⅲ+Ⅳ                   155              96             32                 34.0 (26.0--42.0)                           0.93 (0.71--1.21)             0.572           0.89 (0.68--1.16)    0.397
  unkown                11               7                                                                                                                                                
  **Tumor capsule**                                                                            0.495                                                         0.432                        
  absent                177              113            28                 31.0 (22.7--39.3)                           1.00                                                               
  present               181              110            31                 37.0 (26.1--47.9)                           0.91 (0.70--1.19)             0.499           0.90 (0.69--1.17)    0.439
  unkown                4                2                                                                                                                                                
  **Venous invasion**                                                                          0.026                                                         0.023                        
  absent                257              150            33                 39.0 (29.3--48.7)                           1.00                                                               
  present               102              73             22                 26.0 (20.1--31.9)                           1.37 (1.03--1.81)             0.029           1.38 (1.04--1.82)    0.026
  unkown                3                2                                                                                                                                                
  **Cirrhosis**                                                                                0.706                                                         0.705                        
  absent                121              79             30                 27.0 (13.6--40.4)                           1.00                                                               
  present               239              145            30                 36.0 (29.6--42.4)                           0.95 (0.72--1.25)             0.708           0.95 (0.72--1.25)    0.709
  unkown                2                1                                                                                                                                                
  **Tumor number**                                                                             0.701                                                         0.644                        
  solitary              279              172            30                 34.0 (26.0--42.0)                           1.00                                                               
  multiple              83               53             27                 35.0 (24.5--45.5)                           1.06 (0.78--1.45)             0.704           1.07 (0.79--1.46\_   0.649
  **pTNM stage**                                                                               0.225                                                         0.339                        
  Ⅰ+Ⅱ                   309              188            31                 37.0 (30.7--43.3)                           1.00                                                               
  Ⅲ+Ⅳ                   39               27             24                 22.0 (13.0--31.0)                           1.28 (0.86--1.92)             0.231           1.21 (0.81--1.82)    0.346
  unkown                14               10                                                                                                                                               

MST, median survival time; CI, confidence interval; AFP, serum α-fetoprotein.

Association analysis of SNPs with OS and DFS of HCC patients {#sec009}
------------------------------------------------------------

There are 7 SNPs among CASP genes (*CASP3*, *CASP7*, *CASP8*, *CASP9*, *CASP10*) in the present study. The associations of these genetic polymorphisms with OS and DFS are detailed in [Table 3](#pone.0176802.t003){ref-type="table"}. In univariate analysis, the *CASP3* rs2705897 GT genotype possessed a marginally significant association with decreased OS and DFS, compared with the GG genotype (*P* = 0.072 and 0.078, respectively, [Table 3](#pone.0176802.t003){ref-type="table"}). The *CASP9* rs4645981 CT, CC and CT+CC genotypes were associated with significantly increased DFS, compared with the TT genotype (*P* = 0.012, 0.013 and 0.011, respectively, [Table 3](#pone.0176802.t003){ref-type="table"}, [Fig 1A](#pone.0176802.g001){ref-type="fig"}). However, the *CASP9* rs4645981 CC and CT+CC genotypes showed a marginally significant association with positive effect on OS, compared with the TT genotype (*P* = 0.066 and 0.057, respectively). Furthermore, the rs4645981 CT genotype showed a statistically significant association with OS, compared with the TT genotype (*P* = 0.048, [Table 3](#pone.0176802.t003){ref-type="table"}, [Fig 1B](#pone.0176802.g001){ref-type="fig"}).

![Kaplan-Meier survival curves of *CASP9* rs4645981 with clinical outcomes of 362 HCC patients.\
(A) disease free survival (DFS) (B) overall survival (OS).](pone.0176802.g001){#pone.0176802.g001}
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###### Univariate and multivariate Cox regression analysis of genotypes in HCC patients.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Genotype**               **No of patients**   No of events   5-y-survival   MST\                OS                  DFS                                                                                 
                                                                                (95%CI)                                                                                                                     
  -------------------------- -------------------- -------------- -------------- ------------------- ------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  **CASP3_rs12108497**                                                                                                                                                                                      

  **CC**                     30                   18             46             50.0 (8.0--92.0)    1.0                         1.0                                                                         

  **CT**                     125                  81             36             38.0 (22.5--53.5)   1.32 (0.79--2.20)   0.288   1.35 (0.81--2.25)   0.254   1.45 (0.87--2.43)   0.155   1.49 (0.89--2.49)   0.129

  **TT**                     206                  126            36             31.0 (22.3--39.7)   1.23 (0.75--2.02)   0.404   1.24 (0.76--2.04)   0.388   1.30 (0.79--2.13)   0.302   1.32 (0.80--2.16)   0.274

  **CT+TT**                  331                  207            36             33.0 (26.8--39.2)   1.26 (0.78--2.04)   0.344   1.28 (0.79--2.07)   0.315   1.34 (0.83--2.17)   0.236   1.37 (0.84--2.22)   0.204

  **CASP3_rs2705897**                                                                                                                                                                                       

  **GG**                     10                   5              47             42.0                1.0                         1.0                         1.0                         1.0                 

  **GT**                     96                   69             32             27.0 (17.7--36.3)   2.35 (0.93--5.96)   0.072   2.32 (0.92--5.87)   0.075   2.30 (0.91--5.82)   0.078   2.35 (0.93--5.94)   0.070

  **TT**                     253                  151            38             37.0 (30.3--43.7)   1.49 (0.61--3.64)   0.380   1.63 (0.67--3.99)   0.283   1.52 (0.62--3.71)   0.357   1.68 (0.68--4.10)   0.259

  **GT+TT**                  349                  220            36             33.0 (26.8--39.2)   1.67 (0.69--4.06)   0.259   1.77 (0.73--4.31)   0.207   1.69 (0.70--4.12)   0.245   1.83 (0.75--4.46)   0.182

  ***CASP7*\_rs2227310**                                                                                                                                                                                    

  **CC**                     139                  87             36             33.0 (21.0--45.0)   1.0                         1.0                         1.0                         1.0                 

  **CG**                     158                  95             39             35.0 (27.8--42.2)   0.97 (0.72--1.30)   0.832   0.91 (0.68--1.22)   0.524   0.98 (0.73--1.31)   0.868   0.93 (0.69--1.25)   0.616

  **GG**                     61                   40             33             37.0 (17.5--56.5)   0.98 (0.68--1.43)   0.929   1.01 (0.69--1.48)   0.954   1.03 (0.71--1.50)   0.876   1.06 (0.73--1.55)   0.751

  **CG+GG**                  219                  135            37             37.0 (30.5--43.5)   0.97 (0.74--1.27)   0.844   0.94 (0.72--1.24)   0.669   1.00 (0.76--1.30)   0.960   0.97 (0.74--1.28)   0.828

  ***CASP8*\_rs3769818**                                                                                                                                                                                    

  **CC**                     198                  122            38             38.0 (25.7--50.3)   1.0                         1.0                         1.0                         1.0                 

  **CT**                     123                  76             34             29.0 (18.5--39.5)   1.08 (0.81--1.43)   0.619   1.08 (0.81--1.44)   0.620   1.05 (0.79--1.40)   0.740   1.05 (0.79--1.40)   0.734

  **TT**                     32                   23             33             33.0 (26.5--39.5)   1.18 (0.76--1.84)   0.466   1.16 (0.74--1.81)   0.525   1.24 (0.80--1.94)   0.340   1.22 (0.78--1.92)   0.383

  **CT+TT**                  155                  99             32             31.0 (22.2--39.8)   1.10 (0.84--1.43)   0.495   1.10 (0.84--1.43)   0.514   1.09 (0.84--1.42)   0.528   1.09 (0.83--1.42)   0.546

  ***CASP9*\_rs4645978**                                                                                                                                                                                    

  **AA**                     145                  93             35             37.0 (29.0--45.0)   1.0                         1.0                         1.0                         1.0                 

  **AG**                     165                  99             39             31.0 (18.5--43.5)   0.98 (0.74--1.30)   0.885   0.98 (0.74--1.30)   0.890   1.00 (0.75--0.33)   0.995   1.00 (0.75--1.33)   0.982

  **GG**                     50                   32             34             24.0 (8.0--40.0)    1.11 (0.74--1.66)   0.620   1.11 (0.74--1.66)   0.609   1.12 (0.75--1.67)   0.584   1.11 (0.74--1.65)   0.626

  **AG+GG**                  215                  131            36             31.0 (22.3--39.7)   1.01 (0.77--1.32)   0.952   1.01 (0.77--1.32)   0.953   1.03 (0.79--1.34)   0.854   1.02 (0.78--1.33)   0.883

  ***CASP9*\_rs4645981**                                                                                                                                                                                    

  **TT**                     7                    6              23             8.0 (2.9--13.1)     1.0                         1.0                         1.0                         1.0                 

  **CT**                     84                   50             41             37.0 (27.7--46.3)   0.42 (0.18--0.99)   0.048   0.38 (0.15--0.96)   0.041   0.33 (0.14--0.79)   0.012   0.34 (0.14--0.83)   0.018

  **CC**                     270                  168            36             35.0 (27.0--43.0)   0.47 (0.21--1.05)   0.066   0.51 (0.22--1.17)   0.112   0.35 (0.16--0.80)   0.013   0.37 (0.16--0.86)   0.021

  **CT+CC**                  354                  218            37             35.0 (28.5--41.5)   0.45 (0.20--1.02)   0.057   0.47 (0.21--1.08)   0.077   0.35 (0.15--0.78)   0.011   0.36 (0.16--0.83)   0.016

  ***CASP10*\_rs13006529**                                                                                                                                                                                  

  **AA**                     12                   8              27             42.0 (3.5--80.5)    1.0                         1.0                         1.0                         1.0                 

  **AT**                     109                  62             40             31.0 (17.8--44.2)   0.89 (0.43--1.87)   0.764   0.95 (0.45--2.01)   0.895   0.96 (0.46--2.00)   0.912   1.02 (0.49--2.16)   0.951

  **TT**                     236                  150            37             34.0 (27.1--40.9)   0.92 (0.45--1.87)   0.813   1.02 (0.50--2.09)   0.960   1.04 (0.51--2.12)   0.918   1.20 (0.58--2.47)   0.625

  **AT+TT**                  345                  212            36             34.0 (27.4--40.6)   0.91 (0.45--1.84)   0.789   0.99 (0.49--2.03)   0.987   1.01 (0.50--2.05)   0.977   1.13 (0.56--2.31)   0.733
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MST, median survival time; CI, confidence interval.

^a^ Adjusted by tumor size and venous invasion.

A multivariate analysis of genotype association with OS and DFS of HCC patients was conducted by using Cox proportional hazards model, adjusted for the two significant clinical predictors (tumor size and venous invasion), and the results were similar to the univariate analysis. The GT genotype of *CASP3* rs2705897 showed a suggestively negative effect on OS and DFS of HCC patients, compared with the GG genotype (*P* = 0.075 and 0.070, respectively, [Table 3](#pone.0176802.t003){ref-type="table"}). The *CASP9* rs4645981 CT, CC and CT+CC genotypes were still significantly associated with increased DFS, compared with the TT genotype (*P* = 0.018, 0.021 and 0.016, respectively, [Table 3](#pone.0176802.t003){ref-type="table"}). However, the CT+CC genotype of *CASP9* rs4645981 presented a suggestively positive effect on OS, and the CT genotype of rs4645981 showed a positive effect on OS of HCC patients, compared with the TT genotype (*P* = 0.041, [Table 3](#pone.0176802.t003){ref-type="table"}).

Association analysis of haplotypes with OS and DFS of HCC patients {#sec010}
------------------------------------------------------------------

Since two SNPs in both *CASP3* (rs12108497 T\>C and rs2705897 T\>G) and *CASP9* (rs4645978 A\>G and rs4645981 C\>T) were selected in the present study, we constructed haplotypes for each of the two genes. We examined the associations of these haplotypes with OS and DFS of HCC patients. The detailed information is shown in [Table 4](#pone.0176802.t004){ref-type="table"}. We attained 7 haplotypes in *CASP3* and 6 haplotypes in *CASP9*. In univariate analysis, *CASP3* haplotype TT/TG was significantly associated with OS (*P* = 0.021, [Fig 2A](#pone.0176802.g002){ref-type="fig"}) and DFS (*P* = 0.026, [Fig 2B](#pone.0176802.g002){ref-type="fig"}), compared to the common haplotype TT/TT ([Table 4](#pone.0176802.t004){ref-type="table"}). *CASP9* haplotype GT/GT was significantly associated with decreased DFS and showed marginally associated with OS, compared to the common haplotype AC/AC (*P* = 0.012, [Fig 3](#pone.0176802.g003){ref-type="fig"}, [Table 4](#pone.0176802.t004){ref-type="table"}).

![Kaplan-Meier survival curves of *CASP3*\_haplotype with clinical outcomes of HCC patients.\
(A) overall surviva*l* (OS), and (B) disease free survival (DFS).](pone.0176802.g002){#pone.0176802.g002}

![Kaplan-Meier survival curves of *CASP9*\_haplotype with disease free survival of HCC patients.](pone.0176802.g003){#pone.0176802.g003}
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###### Univariate and multivariate Cox regression analysis of haplotypes in HCC patients.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Haplotype**            **No of patients**   No of events   5-y-survival   MST\                OS                  DFS                                                                                 
                                                                              (95%CI)                                                                                                                     
  ------------------------ -------------------- -------------- -------------- ------------------- ------------------- ------- ------------------- ------- ------------------- ------- ------------------- -------
  ***CASP3*\_haplotype**                                                                                                                                                                                  

  **TT/TT**                183                  108            37             33.0 (25.7--40.4)   1.0                         1.0                         1.0                         1.0                 

  **CG/CG**                10                   5              47             42.0                0.69 (0.28--1.69)   0.416   0.64 (0.26--1.58)   0.333   0.68 (0.28--1.66)   0.395   0.62 (0.25--1.53)   0.299

  **CG/TT**                62                   43             34             36.0 (14.3--57.7)   1.19 (0.84--1.70)   0.325   1.19 (0.83--1.69)   0.350   1.26 (0.88--1.79)   0.202   1.26 (0.88--1.80)   0.200

  **CT/CG**                12                   8              36             26.0 (10.7--41.7)   1.08 (0.53--2.21)   0.840   0.98 (0.47--2.02)   0.954   1.00 (0.49--2.05)   0.996   0.90 (0.44--1.86)   0.782

  **CT/CT**                8                    5              60             72.0(27.4--116.6)   0.80 (0.33--1.96)   0.622   0.97 (0.39--2.41)   0.939   0.78 (0.32--1.92)   0.592   0.97 (0.39--2.42)   0.939

  **TT/CT**                61                   38             36             38.0 (23.4--52.6)   1.07 (0.74--1.54)   0.735   1.12 (0.77--1.62)   0.562   1.10 (0.76--1.60)   0.607   1.13 (0.78--1.64)   0.512

  **TT/TG**                22                   18             24             17.0 (8.0--26.0)    1.81 (1.09--2.98)   0.021   1.77 (1.08--2.93)   0.025   1.77 (1.07--2.91)   0.026   1.74 (1.05--2.87)   0.030

  ***CASP9*\_haplotype**                                                                                                                                                                                  

  **AC/AC**                145                  93             35             37.0 (19.0--45.0)   1.0                         1.0                         1.0                         1.0                 

  **AC/GC**                100                  61             36             30.0 (15.4--44.6)   1.06 (0.76--1.46)   0.742   1.10 (0.79--1.52)   0.574   1.09 (0.79--1.51)   0.590   1.12 (0.81--1.55)   0.504

  **GC/GC**                24                   13             42             26.0 (2.9--49.1)    0.89 (0.50--1.60)   0.704   0.87 (0.49--1.57)   0.653   0.88 (0.49--1.58)   0.678   0.83 (0.46--1.51)   0.549

  **GC/GT**                19                   13             28             33.0 (11.4--54.6)   1.14 (0.64--2.03)   0.666   1.23 (0.68--2.21)   0.498   1.11 (0.62--1.99)   0.717   1.18 (0.66--2.13)   0.571

  **GT/AC**                64                   37             43             38.0 (19.7--56.3)   0.87 (0.59--1.27)   0.462   0.83 (0.56--1.21)   0.328   0.87 (0.59--1.27)   0.464   0.83 (0.57--1.22)   0.340

  **GT/GT**                7                    6              23             8.0 (2.9--13.1)     2.19 (0.95--5.02)   0.064   2.35 (0.98--5.64)   0.055   2.91 (1.26--6.71)   0.012   3.16 (1.32--7.57)   0.010
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MST, median survival time; CI, confidence interval.

^a^ Adjusted by tumor size and venous invasion.

Similar results were found in multivariate analysis adjusted for tumor size and venous invasion. The *CASP3* haplotype TT/TG presented a negative effect on OS (*P* = 0.025) and DFS (*P* = 0.030) of HCC patients, compared to the common haplotype TT/TT ([Table 4](#pone.0176802.t004){ref-type="table"}). Meanwhile, *CASP9* haplotype GT/GT presented a negative effect on DFS (*P* = 0.010) and suggestively negative effect on OS (*P* = 0.055) of HCC patients, compared to the common haplotype AC/AC ([Table 4](#pone.0176802.t004){ref-type="table"}).

Discussion {#sec011}
==========

Though many investigations have reported associations of SNPs in CASP genes with several types of cancer, studies of genetic polymorphisms in CASP genes on susceptibility to HCC is few, not to mention relationship between CASP polymorphisms and prognosis of HCC. The aim of our study was to evaluate genetic variants of CASP genes in relation to survival outcomes of HCC patients. To the best of our knowledge, this is the first evidence showing the relationship between genetic polymorphisms of CASP genes and prognosis of HCC patients. Our results revealed that *CASP9* rs4645981 C allele was significantly increased DFS compared with the T allele and only the CT genotype was significantly associated with positive effect on OS, compared with the TT genotype. Moreover, the haplotype TT/TG (constructed by rs12108497 T\>C, rs2705897 T\>G) in *CASP3* gene was significantly associated with decreased OS and DFS. The haplotype GT/GT in *CASP*9 was only significantly associated with decreased DFS. These findings suggest that the *CASP9* rs4645981 and the haplotype TT/TG in *CASP3 and* GT/GT in *CASP*9 may be useful markers for predicting prognosis of HCC patients.

Failure of apoptosis is a hallmark of human cancers. As an effector CASP, *CASP3* plays an important role in the execution phase of apoptosis, also in the development and progression of cancers \[[@pone.0176802.ref016]--[@pone.0176802.ref017]\]. Several previous studies have shown associations of *CASP3* polymorphisms on the risk of different types of cancer, including HCC \[[@pone.0176802.ref013], [@pone.0176802.ref018]--[@pone.0176802.ref020]\]. Moreover, studies in several tumor types indicated that the expression levels of *CASP3* have effects on the development and survival of cancers \[[@pone.0176802.ref008], [@pone.0176802.ref017], [@pone.0176802.ref021]\]. In our study, the haplotype TT/TG (constructed by rs12108497 T\>C, rs2705897 T\>G) was significantly associated with decreased OS and DFS in patients with HCC. The findings of previous studies and ours suggest that polymorphisms in *CASP3* may increase risk of development of HCC and lead to poor survival outcome in patients with HCC, through reducing the apoptotic capacity.

CASPs have two distinct but converging pathways for activation, including extrinsic pathway and intrinsic pathway. *CASP9*, an important initiator CASP of the intrinsic pathway, is activated by the release of cytochrome c from mitochondria, activates downstream the effector *CASP3* and *CASP7* \[[@pone.0176802.ref022]--[@pone.0176802.ref023]\]. Many previous studies have shown that polymorphisms in *CASP9* were associated with various cancer types, especially in the promoter region. For example, Theodoropoulos GE et al. \[[@pone.0176802.ref022]\] evaluated the association between two SNPs (rs4645978, rs4645981) in the promoter region of *CASP9* and the risk of breast cancer. They found that the rs4645978 G allele was at high risk for breast cancer development and similar results for the rs4645981 T allele, which was significantly associated with increased risk of breast cancer, compared with those harboring the CC genotype. However, [Park JY](https://www.ncbi.nlm.nih.gov/pubmed/?term=Park%20JY%5bAuthor%5d&cauthor=true&cauthor_uid=16687442) et al. \[[@pone.0176802.ref024]\] found that *CASP9* rs4645978 polymorphism played a protective role in susceptibility to lung cancer risk and the rs4645981 T allele was at a significantly increased risk of lung cancer compared with those harboring the CC genotype. Moreover, previous studies demonstrated that *CASP9* polymorphisms and expression were associated with prognosis of cancers \[[@pone.0176802.ref025]--[@pone.0176802.ref026]\]. To our best knowledge, the present study showed the first evidence of association between polymorphisms in *CASP9* and the prognosis of HCC patients.

We acknowledge that there were several limitations in our study. First, the sample size of the present study was relatively small. Therefore, larger sample size and follow-up studies are warranted to confirm our findings. Second, determination of the exact functional influence was not performed in our study. Functional studies on biological mechanisms are needed to investigate in further studies. Third, other treatment information such as whether or not receiving targeted therapy was not collected in our study, except for surgery which is the most important factor for prognosis of patients. Finally, though two clinical and pathologic characteristics showed significant associations with OS and DFS, including tumor size and venous invasion, it is regretful that we failed to collect accurate information of these factors in our study. We only performed multivariate analysis by adjusting these potential prognostic factors. Further studies are essential to evaluate the role of genetic polymorphisms in HCC patients with more complete and comprehensive clinical pathologic characteristics.

In conclusion, our results provide suggestive evidence that *CASP9* and *CASP3* genetic polymorphisms may be independent prognosis markers for HCC patients with surgical resection of tumor. This study is the first evidence showing the relationship between genetic polymorphisms of CASP genes and survival outcomes in HCC patients, more comprehensive studies are needed to confirm our findings and investigate the associations between CASP genetic polymorphisms and prognosis of HCC patients.
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###### Association analysis of clinical characteristics, genotypes and haplotypes with OS and DFS of HCC patients.
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Click here for additional data file.

We thank all the participants in this study.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** DKJ LY JFX.**Data curation:** DKJ.**Formal analysis:** SZ GPY HTC.**Funding acquisition:** DKJ LY JFX.**Investigation:** DKJ SZ.**Methodology:** QYX ZQS XPM PYZ.**Project administration:** DKJ.**Resources:** TYC PXL NJW WHR HXGSY SQS PH JX.**Writing -- original draft:** SZ.**Writing -- review & editing:** DKJ CC SLZ.
